Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~8 mi. (Dublin, Ireland, +247 more cities)

St. James'S Hospital

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~8 mi. (Dublin, Ireland, +356 more cities)

Saint Vincents University Hospital

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

~8 mi. (Dublin, Ireland, +174 more cities)

Local Institution

Non-Small Cell Lung Carcinoma

chemoradiotherapy, +3 more drugs

chemotherapy, +2 more types

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

~8 mi. (Dublin, Ireland, +234 more cities)

Beacon Hospital

Prostate Adenocarcinoma

stereotactic body radiation therapy

radiation therapy, +1 more type

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~8 mi. (Dublin, Ireland, +137 more cities)

St. James s Hospital ( Site 1601)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

~8 mi. (Rathgar, Ireland, +46 more cities)

St. Luke's Hospital

Prostate Adenocarcinoma

darolutamide, +2 more drugs

hormone therapy, +1 more type

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

~8 mi. (Dublin, Ireland, +145 more cities)

Local Institution

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Carcinoma

ipilimumab, +1 more drug

immunotherapy

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~8 mi. (Dublin, Ireland, +105 more cities)

Mater Misericordiae University Hospital ( Site 1654)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

~8 mi. (Dublin, Ireland, +85 more cities)

Investigational Site Number :3720002

Smoldering Plasma Cell Myeloma

dexamethasone, +2 more drugs

chemotherapy, +2 more types

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~8 mi. (Dublin, Ireland, +228 more cities)

St James Hospital /ID# 205104

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

~8 mi. (Dublin, Ireland, +387 more cities)

Saint Lukes Hospital

ERBB2 Amplification

Breast Carcinoma

radiation therapy

radiation therapy

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

~8 mi. (Dublin, Ireland, +118 more cities)

Regeneron Research Site

Skin Squamous Cell Carcinoma

cemiplimab

immunotherapy